Evaluating the Effect of melatonin on mechanically ventilated COVID 19 patients

Evaluating the Effect of melatonin on mechanically ventilated COVID 19 patients in Intensive care unit

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20210225050495N1

Enrollment

Registered

2021-10-01

Start date

2021-08-11

Completion date

Unknown

Last updated

2021-11-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

critical COVID19. U07.1 COVID-19, virus identified

Interventions

Intervention 1: Patients in melatonin group will receive 21mg of melatonin (Razak) every night for 5 days through nasogastric tubr. Intervention 2: Control group: Placebo group will receive placebo pr

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: all covid-19 patients admitted to the ICU Mechanically ventilated patients within the first 24 hours of intubation

Exclusion criteria

Exclusion criteria: liver enzyme more than 5 times of normal upper limit

Design outcomes

Primary

Measure	Time frame
In ICU Mortality Percent. Timepoint: At the end of the study. Method of measurement: The Number of Alive patients at the end of the study in each group.;The duration of the mechanical ventilation. Timepoint: at the end of the study. Method of measurement: Calculating the total days of mechanical ventilation.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHadiseh Hosamirudsari

Tehran University of Medical Sciences

h-hosami@sina.tums.ac.ir+98 21 5565 8500

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026